<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30041178</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>07</Month>            <Day>31</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1423-0232</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>94 Suppl 1</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Oncology</Title>                <ISOAbbreviation>Oncology</ISOAbbreviation>            </Journal>            <ArticleTitle>Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.</ArticleTitle>            <Pagination>                <MedlinePgn>34-44</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000489067</ELocationID>            <Abstract>                <AbstractText>Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic chemotherapy, endocrine- or human epidermal growth factor receptor 2 (HER2)-targeted therapy, and palliative therapy. However, no standard approach has been clearly identified for second and further chemotherapy lines in MBC patients. In the phase III clinical trial EMBRACE, eribulin was particularly effective in reducing liver lesions and improving both overall survival and progression-free survival in liver MBC patients. In this series, we collected 8 case reports of Italian clinical practice in which eribulin has shown significant efficacy in reducing liver metastases in MBC patients: complete response was reported in 2 patients, and 4 patients achieved partial response. The treatment was well tolerated, thus confirming that eribulin is a suitable therapeutic option for elderly patients and for those who have metastatic HER2-negative disease. In the setting of MBC, the sequencing of therapeutic agents should consider expected response, side effects, tumor characteristics, and patient's preferences, in order to successfully tailor the most appropriate therapy beyond earlier lines.</AbstractText>                <CopyrightInformation>© 2018 S. Karger AG, Basel.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Giordano</LastName>                    <ForeName>Guido</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Oncology Unit, San Filippo Neri Hospital, Rome, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Oncology Division, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Febbraro</LastName>                    <ForeName>Antonio</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Oncology Unit, &quot;Sacro Cuore di Gesù Fatebenefratelli&quot; Hospital, Benevento, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Quaquarini</LastName>                    <ForeName>Erica</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Operative Unit of Medical Oncology, ICS Maugeri-IRCCS, Pavia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Turletti</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>ASL Città di Torino, Ospedale Martini, Turin, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pedersini</LastName>                    <ForeName>Rebecca</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Breast Unit-Oncology Department, Spedali Civili Hospital, Brescia, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Raffaele</LastName>                    <ForeName>Mimma</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>UOSD Oncologia Presidio Cassia, Sant'Andrea-Dipartimento Oncologico ASL, Rome, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Villa</LastName>                    <ForeName>Federica</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>S.C. Oncologia Medica, Dipartimento Oncologico Aziendale, ASST Lecco, Lecco, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rossello</LastName>                    <ForeName>Rosalba</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Oncologia Medica dell'Ospedale S. Vicenzo di Taormina, Taormina, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <CollectiveName>The Italian Eribulin Working Group</CollectiveName>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D002363">Case Reports</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>24</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Oncology</MedlineTA>            <NlmUniqueID>0135054</NlmUniqueID>            <ISSNLinking>0030-2414</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D005663">Furans</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D007659">Ketones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>LR24G6354G</RegistryNumber>                <NameOfSubstance UI="C490954">eribulin</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2008 Jul;7(7):2003-11</RefSource>                <PMID Version="1">18645010</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2013 Apr;49(6):1374-403</RefSource>                <PMID Version="1">23485231</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ther Adv Med Oncol. 2013 Nov;5(6):334-50</RefSource>                <PMID Version="1">24179488</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2012 Sep 28;12:435</RefSource>                <PMID Version="1">23020297</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2011 Mar 12;377(9769):914-23</RefSource>                <PMID Version="1">21376385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2009 Jun;10(6):615-21</RefSource>                <PMID Version="1">19482250</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2005 Jul;4(7):1086-95</RefSource>                <PMID Version="1">16020666</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Geriatr Oncol. 2018 May;9(3):281-283</RefSource>                <PMID Version="1">29174186</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2014 Jun;19(6):608-15</RefSource>                <PMID Version="1">24794159</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2006 Apr 1;106(7):1624-33</RefSource>                <PMID Version="1">16518827</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg. 2006 Dec;244(6):897-907; discussion 907-8</RefSource>                <PMID Version="1">17122615</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2017 Apr;13(11s):11-23</RefSource>                <PMID Version="1">28481185</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2014 Dec;148(3):553-61</RefSource>                <PMID Version="1">25381136</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2014 Apr;19(4):318-27</RefSource>                <PMID Version="1">24682463</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2017 Jan 1;28(1):16-33</RefSource>                <PMID Version="1">28177437</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Womens Health. 2015 Jan 06;7:47-58</RefSource>                <PMID Version="1">25610001</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Ther. 2017 Aug;39(8):1719-1728</RefSource>                <PMID Version="1">28751098</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer. 2008;15(1):35-9</RefSource>                <PMID Version="1">18224392</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Chemother Pharmacol. 2012 Dec;70(6):823-32</RefSource>                <PMID Version="1">23010853</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Feb 20;33(6):594-601</RefSource>                <PMID Version="1">25605862</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2001 Feb 1;61(3):1013-21</RefSource>                <PMID Version="1">11221827</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007659" MajorTopicYN="N">Ketones</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Eribulin</Keyword>            <Keyword MajorTopicYN="N">Liver metastasis</Keyword>            <Keyword MajorTopicYN="N">Metastatic breast cancer</Keyword>            <Keyword MajorTopicYN="N">Quality of life</Keyword>        </KeywordList>        <InvestigatorList>            <Investigator ValidYN="Y">                <LastName>Amoroso</LastName>                <ForeName>V</ForeName>                <Initials>V</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Antonelli</LastName>                <ForeName>G</ForeName>                <Initials>G</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Ardizzoia</LastName>                <ForeName>A</ForeName>                <Initials>A</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Bernardo</LastName>                <ForeName>A</ForeName>                <Initials>A</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Berruti</LastName>                <ForeName>A</ForeName>                <Initials>A</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Claps</LastName>                <ForeName>M</ForeName>                <Initials>M</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Colina</LastName>                <ForeName>P</ForeName>                <Initials>P</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Crippa</LastName>                <ForeName>A</ForeName>                <Initials>A</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>D'Andrea</LastName>                <ForeName>M</ForeName>                <Initials>M</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Febbraro</LastName>                <ForeName>A</ForeName>                <Initials>A</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Ferraù</LastName>                <ForeName>F</ForeName>                <Initials>F</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Frascaroli</LastName>                <ForeName>M</ForeName>                <Initials>M</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Giordano</LastName>                <ForeName>G</ForeName>                <Initials>G</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Grisanti</LastName>                <ForeName>S</ForeName>                <Initials>S</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Massa</LastName>                <ForeName>G</ForeName>                <Initials>G</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Palumbo</LastName>                <ForeName>R</ForeName>                <Initials>R</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Pedersini</LastName>                <ForeName>R</ForeName>                <Initials>R</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Quaquarini</LastName>                <ForeName>E</ForeName>                <Initials>E</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Raffaele</LastName>                <ForeName>M</ForeName>                <Initials>M</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Roca</LastName>                <ForeName>E</ForeName>                <Initials>E</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Simoncini</LastName>                <ForeName>E L</ForeName>                <Initials>EL</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Sottotetti</LastName>                <ForeName>F</ForeName>                <Initials>F</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Spagnoletti</LastName>                <ForeName>I</ForeName>                <Initials>I</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Spagnuolo</LastName>                <ForeName>A</ForeName>                <Initials>A</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Tagliaferri</LastName>                <ForeName>B</ForeName>                <Initials>B</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Turletti</LastName>                <ForeName>A</ForeName>                <Initials>A</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Vassalli</LastName>                <ForeName>L</ForeName>                <Initials>L</Initials>            </Investigator>            <Investigator ValidYN="Y">                <LastName>Villa</LastName>                <ForeName>F</ForeName>                <Initials>F</Initials>            </Investigator>        </InvestigatorList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>25</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30041178</ArticleId>            <ArticleId IdType="pii">000489067</ArticleId>            <ArticleId IdType="doi">10.1159/000489067</ArticleId>            <ArticleId IdType="pmc">PMC6193749</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>